Miller M I, Puchner P J
Department of Urology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.
Urology. 1998 Feb;51(2):237-40. doi: 10.1016/s0090-4295(97)00614-6.
To report long-term follow-up in 18 patients with gross hematuria associated with benign prostatic hyperplasia (BPH) who have been treated with finasteride and to report preliminary follow-up in an additional 10 patients.
The charts of the 18 original patients, and 10 additional patients who had been placed on finasteride (5 mg daily) for intermittent gross hematuria associated with BPH, were reviewed. All had evaluations that were negative for tumor. A hematuria grading system was devised using grades 0, 1, 2, and 3 (grade 0 the least severe, grade 3 the most severe hematuria).
Sixteen of 18 patients have continued finasteride therapy. Mean follow-up is 31 months (range 10 to 47). Twelve had undergone prior prostatectomy. In this group, 3 patients had grade 1, 5 grade 2, and 4 grade 3 hematuria prior to treatment with finasteride. During finasteride therapy, 9 patients had grade 0, 2 grade 1 (pretreatment grades 2 and 3), and 1 grade 3 (pretreatment grade 3) hematuria. Of the 4 patients without prior prostate surgery, 2 had grade 0 (pretreatment grades 1 and 3), and 2 had grade 1 (pretreatment grade 2) hematuria. In summary, 14 of 16 patients improved according to their hematuria grade. We have since added another 10 patients to our study, with a mean follow-up of 11 months. Six of 7 patients who had previous prostatectomies in this group now have grade 0 hematuria. Overall, 8 of the 10 have improved according to hematuria grade.
Long-term follow-up has confirmed the efficacy of finasteride in treating gross hematuria associated with BPH and we now recommend finasteride as first line therapy in the treatment of BPH-associated gross hematuria. reserved.
报告18例因良性前列腺增生（BPH）导致肉眼血尿且接受非那雄胺治疗患者的长期随访情况，并报告另外10例患者的初步随访情况。
回顾了18例原患者以及另外10例因BPH相关间歇性肉眼血尿而接受非那雄胺（每日5毫克）治疗患者的病历。所有患者的肿瘤评估均为阴性。设计了一个血尿分级系统，分为0、1、2和3级（0级最轻微，3级血尿最严重）。
18例患者中有16例继续接受非那雄胺治疗。平均随访时间为31个月（范围10至47个月）。其中12例患者曾接受过前列腺切除术。在该组中，3例患者在接受非那雄胺治疗前为1级血尿，5例为2级血尿，4例为3级血尿。在非那雄胺治疗期间，9例患者为0级血尿，2例为1级血尿（治疗前为2级和3级），1例为3级血尿（治疗前为3级）。在4例未接受过前列腺手术的患者中，2例为0级血尿（治疗前为1级和3级），2例为1级血尿（治疗前为2级）。总之，16例患者中有14例血尿分级有所改善。此后我们又纳入了10例患者进行研究，平均随访时间为11个月。该组中7例曾接受过前列腺切除术的患者中有6例现在为0级血尿。总体而言，10例患者中有8例血尿分级有所改善。
长期随访证实了非那雄胺治疗BPH相关肉眼血尿的疗效，我们现在推荐非那雄胺作为治疗BPH相关肉眼血尿的一线治疗药物。保留。
